PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsGlucagon
Glucagon, Baqsimi(glucagon)
Baqsimi, Glucagon, Gvoke, Ogluo (glucagon) is a protein pharmaceutical. Glucagon was first approved as Glucagon on 1982-01-01. It is used to treat anaphylaxis, bradycardia, cardiogenic shock, hypoglycemia, and hypotension in the USA. It has been approved in Europe to treat diabetes mellitus. The pharmaceutical is active against glucagon receptor. In addition, it is known to target glucagon-like peptide 2 receptor and glucagon-like peptide 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Baqsimi, Glucagon, Gvoke vialdx (discontinued: Glucagen, Glucagon, Gvoke vialdx)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glucagon hydrochloride
Tradename
Company
Number
Date
Products
GLUCAGONFresenius KabiN-201849 RX2015-05-08
2 products, RLD, RS
Show 2 discontinued
Glucagon
Tradename
Company
Number
Date
Products
BAQSIMIAmphastar PharmaceuticalsN-210134 RX2019-07-24
1 products, RLD, RS
GVOKE PFSXeris PharmaceuticalsN-212097 RX2019-09-10
1 products, RLD, RS
GVOKE HYPOPENXeris PharmaceuticalsN-212097 RX2019-09-10
2 products, RLD, RS
GVOKE KITXeris PharmaceuticalsN-212097 RX2021-08-20
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
baqsimiNew Drug Application2025-08-06
glucag0nNew Drug Application2022-12-09
glucagonANDA2026-04-24
glucagon glucagonNew Drug Application2019-05-22
gvoke hypopen gvoke kit gvoke pfsNew Drug Application2023-01-10
gvoke hypopen gvoke pfsNew Drug Application2021-07-15
gvoke hypopen gvoke kit gvoke pfsNew Drug Application2025-12-23
gvoke hypopen gvoke pfsNew Drug Application2019-09-10
gvoke vialdxNew Drug Application2025-03-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypotensionEFO_0005251D007022I95
cardiogenic shock—D012770R57.0
anaphylaxis—D000707T78.2
hypoglycemia—D007003E16.2
bradycardia—D001919R00.1
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Glucagon, Baqsimi, Amphastar Pharms Inc
107656022039-09-23DP
108941332038-01-03DP
102134872036-02-16DPU-2604
Glucagon, Gvoke Hypopen, Xeris
96493642036-04-22DPU-2742
115902052036-04-22DPU-2742
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H04: Pancreatic hormones
— H04A: Glycogenolytic hormones
— H04AA: Glycogenolytic hormones
— H04AA01: Glucagon
HCPCS
Code
Description
J1610
Injection, glucagon hydrochloride, per 1 mg
J1611
Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg
Clinical
Clinical Trials
1446 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11715595111153473
Diabetes mellitusD003920EFO_0000400E08-E1382738971113409
ObesityD009765EFO_0001073E66.95177607391339
Type 1 diabetes mellitusD003922EFO_0001359E104167401666207
OverweightD050177—E66.32234292033134
HypoglycemiaD007003—E16.22329151031102
Healthy volunteers/patients———393741869
Insulin resistanceD007333EFO_0002614E88.81917166102266
Weight lossD015431——4129192063
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8168241432
Show 121 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nutrition disordersD009748EFO_0001069—939—122
Glucose metabolism disordersD044882——233—1321
Congenital hyperinsulinismD044903——563—212
HyperinsulinismD006946—E16.1841—312
Endocrine system diseasesD004700EFO_0001379E34.9323—311
InfarctionD007238EFO_0009463——11—810
StrokeD020521EFO_0000712I63.9—31—59
Ischemic strokeD000083242———53—18
Cystic fibrosisD003550EFO_0000390E84121—47
NesidioblastosisD046768EFO_0007318E16.9321—26
Show 31 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlcoholismD000437EFO_0003829F10.118——110
Endometrial neoplasmsD016889EFO_0004230—24———6
Cutis laxaD003483—Q82.8—2——35
Smoking cessationD016540EFO_0004319—14———4
Addictive behaviorD016739EFO_0004347——4———4
Alcoholic fatty liverD005235—K70.021——24
MalnutritionD044342EFO_0008572E40-E46—1——34
Heart diseasesD006331EFO_0003777I51.9—2——24
Exocrine pancreatic insufficiencyD010188—K86.81—1——23
Parkinson diseaseD010300EFO_0002508G2012———3
Show 63 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlucagonomaD005935——1———45
InsulinomaD007340——1———34
Physiological phenomenaD010829——1———12
Carcinoid tumorD002276—D3A.001————1
Cocaine-related disordersD019970—F141————1
Myocardial reperfusion injuryD015428EFO_0002687—1————1
PintaD010874EFO_1001396A671————1
GlycosuriaD006029—R811————1
Common coldD003139EFO_0007214J001————1
Gastrointestinal diseasesD005767——1————1
Show 14 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80————55
Respiratory aspiration of gastric contentsD063466——————55
Stomach neoplasmsD013274EFO_0003897C16————44
Heart disease risk factorsD000082742——————44
Esophageal neoplasmsD004938—C15————33
Brain injuriesD001930—S06.9————22
Pituitary diseasesD010900—E23.7————22
Diabetes insipidusD003919—E23.2————22
AdiposityD050154——————22
Blood circulationD001775——————22
Show 78 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGlucagon
INNglucagon
Description
Glucagon is a 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O
Identifiers
PDB—
CAS-ID9007-92-5
RxCUI—
ChEMBL IDCHEMBL266481
ChEBI ID5391
PubChem CID16132283
DrugBankDB00040
UNII ID76LA80IG2G (ChemIDplus, GSRS)
Target
Agency Approved
GCGR
GCGR
Organism
Homo sapiens
Gene name
GCGR
Gene synonyms
NCBI Gene ID
2642
Protein name
glucagon receptor
Protein synonyms
Uniprot ID
Q2M3M5
Mouse ortholog
Gcgr (14527)
glucagon receptor (Q8K0B5)
Alternate
GLP2R
GLP2R
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP2R
Gene synonyms
NCBI Gene ID
9340
Protein name
glucagon-like peptide 2 receptor
Protein synonyms
epididymis secretory sperm binding protein, GLP-2 receptor
Uniprot ID
Q4VAT3
Mouse ortholog
Glp2r (93896)
glucagon-like peptide 2 receptor (Q5SU65)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Gvoke – Xeris Biopharma Holdings
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Baqsimi – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Baqsimi – Amphastar Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Glucagon – Amphastar Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Glucagon
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 11,790 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,037 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use